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We have studied infectivity and neutralization of X4, R5, and R5X4 tropic HIV-1 mutants, which are lacking N-linked
glycosylation sites for glycans g13, g14, g15, and g17 in the V3 loop region of gp120. X4-tropic NL4-3 mutants lacking
combinations of g14/15 or g15/17 showed markedly higher infectivity in CXCR4-specific infection. The role of g15 in
CCR5-specific infection was investigated using viruses with high (NL-918, R5-monotropic), medium (NL-991, R5-monotropic),
and low (NL-952, R5X4-dualtropic) CCR5-specific infectivity. For NL-991, a reduction of infectivity on GHOST-CCR5 cells was
observed for a mutant lacking g15. For NL-952 mutants all lacking g15, a complete loss of CCR5-specificity was observed
and NL-952 was shifted from R5X4 to X4 tropism. For all mutants of NL4-3, NL-991, and NL-952, where the lack of g15
markedly influenced infectivity or coreceptor usage, neutralization was enhanced. In contrast, NL-918 mutants with or without
g15 showed no difference in neutralization and no difference in GHOST-CCR5 infection rates. Thus, for viruses with a low or
medium CCR5-specificity the role of g15 for changing CCR5-usage and sensitivity to neutralization was more significant than
for viruses with high infection rates on GHOST-CCR5 cells. Our data demonstrate that V3 glycans play an important role in
the usage of CXCR4 and CCR5. The lack of g15 was relevant for a more efficient use of CXCR4, whereas interaction with
CCR5 was facilitated in the presence of g15. This study also demonstrates that glycan g15 is involved in blocking ofINTRODUCTION
The human immunodeficiency virus type-1 (HIV-1) ex-
ternal glycoprotein gp120 mediates cell entry by binding
specific receptors on the surface of the target cell. These
receptors are CD4 (Dalgleish et al., 1984; Klatzmann et
al., 1984) and chemokine receptors identified as the
HIV-1 coreceptors (Alkhatib et al., 1996; Deng et al., 1996;
Feng et al., 1996; Dragic et al., 1996). The chemokine
receptors CXCR4 and CCR5 are the two major corecep-
tors used by HIV-1 isolates (Zhang et al., 1996). All known
virus isolates are at least using CXCR4 or CCR5 for viral
entry. Viruses using only CXCR4 are called X4 mono-
tropic viruses, whereas viruses using only CCR5 are R5
monotropic. In addition to these monotropic isolates,
viruses able to infect cells using CCR5 and CXCR4 are
identified, designated R5X4 dualtropic viruses (Collmann
et al., 1992; Doranz et al., 1996; Simmons et al., 1996).
In addition to CXCR4 and CCR5, several other chemo-
kine receptors are known to act as cofactors for viral
entry (Berger et al., 1998). However, viral infectivity in vivo
was always identified in correlation to CXCR4 or CCR5
usage, indicating that these two coreceptors play a dom-
1 To whom correspondence and reprint requests should be ad-
dressed at Bernhard Nocht Institute for Tropical Medicine, Bernhardinant role for viral infectivity and AIDS pathogenesis
(Zhang et al., 1998a,b). Early in infection, R5 monotropic
HIV-1 isolates are predominant in patients. During dis-
ease progression, viruses can be detected which are
using CXCR4 in addition to CCR5 (Smyth et al., 1998) and
finally, X4-monotropic viruses are emerging in late
stages of infection. The emergence of the X4 isolates in
patients correlates with the transition from the asymp-
tomatic to the symptomatic stage of HIV infection and the
development of AIDS (Tersmette et al., 1988, 1989;
Schuitemaker et al., 1992).
While the mechanism of coreceptor switching from R5
to X4 tropism is still unclear, the interactions between the
gp120 and the two coreceptors CXCR4 and CCR5 are
better understood. Based on indirect experimental ap-
proaches, such as site-directed mutagenesis and infec-
tivity studies using the resulting recombinant viruses, a
role of the gp120 V3 loop in determining coreceptor
usage was clearly demonstrated (DeJonge et al., 1992;
Cocchi et al., 1996).
The V3 loop is one of the five variable regions of the
envelope protein gp120, a protein that is extensively
glycosylated, containing 24–26 potential glycosylation
sites (24 for HIV-1NL4-3 strain, 26 for HIV-1SF2) (Zhu et al.,
2000). The various glycans present at these sites repre-neutralizing antibodies and shifting HIV tropism from R5X4
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glycosylation sites, designated g13, g14, g15, g16, and
g17, are located in the V3 loop region (see Fig. 1).
Recently we have demonstrated that two of these
glycans play a role in CXCR4-specific infection (Polzer et
al., 2001). Infectivity and resistance against SDF-1 inhi-
bition of HIVNL4-3 mutants lacking glycan g15 was en-
hanced in contrast to mutants containing fully glycosy-
lated V3 loop. The lack of the two V3 glycans g15 and g17,
especially, markedly enhanced infectivity and SDF-1 re-
sistance for CXCR4-expressing cells. To study the func-
tion of V3 loop glycans, most site-directed mutagenesis
studies have been conducted with X4 tropic HIV-1 strains
(Schonning et al., 1996a,b; Nakayama et al., 1998; Los-
man et al., 1999) and only limited data are available for
R5X4 dualtropic viruses (Ogert et al., 2001; Pollakis et al.,
2001).
Therefore, we have investigated the role of V3 loop
carbohydrates for viral infectivity using a complete set of
X4, R5X4, but also R5 monotropic viruses. R5 and R5X4
mutants were constructed by transferring the V3 region
of HIV primary isolates into the HIVNL4-3 molecular clone.
Thus, all mutants had an identical genetic background
only differing in the V3 loop region. Based on these X4,
R5, and R5X4 viruses, 24 mutants with different combi-
nations of the N-glycosylation sites g13, g14, g15, and
g17 in the V3 region were constructed and tested for
coreceptor-specific infection and neutralization.
This study presents conclusive evidence that V3 loop
glycans are affecting the interaction between gp120 and
the coreceptors CCR5 and CXCR4 in a different manner.
In CXCR4-specific infection glycans are masking the V3
loop and lack various high mannose (HM) and complex
sugars (C), i.e., g14 (HM), g15 (C), and g17 (HM) markedly
enhanced CXCR4-dependent infectivity. In CCR5-specific
infection the lack of g15 was down-regulating the CCR5-
specific infectivity of R5 tropic viruses. Interestingly, the
CCR5-specificity of a R5X4 dualtropic virus was com-
pletely lost due to the lack of g15. Altogether, our data
demonstrate that glycan g15 especially plays an impor-
tant role in gp120—coreceptor interaction and also in
shifting the viral phenotype from R5 to X4 monotropism.
RESULTS
Generation of NL4-3 mutants of X4, R5,
and R5X4 phenotype
The NL4-3 wild-type virus is a X4 monotropic virus
(X4-NL4-3) presenting a V3 region with five sites for
N-linked glycosylation (Fig. 1). To study the role of V3
loop glycans for coreceptor interactions of R5 and R5X4,
tropic viruses the V3 region of X4-NL4-3 was replaced by
the V3 region of the three primary isolates PI-991, PI-918,
and PI-952. The resulting mutants were designated R5-
918, R5-991, and R5X4-952. Based on these viruses, we
have constructed mutants differing in V3 loop glycosyla-
tion (Fig. 2). Five mutants of X4-NL4-3 were constructed
to study the role of g14 and g15 for viral infectivity. Twelve
R5X4-952 mutants were constructed differing in the pres-
ence of glycosylation sites g13, g14, g15, and g17 and
three R5-918 and R5-991 mutants of these R5 monotropic
viruses were generated differing in g15 and g17.
Changes of the glycosylation sites were made by altering
the recognition site for N-linked glycosylation as de-
scribed earlier (Polzer et al., 2001) or according to other
reports in the literature (Ogert et al., 2001; Reitter et al.,
1998; Nakayama et al., 1998; Losman et al., 1999; Cheng-
Mayer et al., 1999). In total 24 NL4-3 mutants were
generated, differing in V3 loop amino acid sequence and
presence of glycosylation sites to analyze CXCR4- and
CCR5-dependent infectivity.
Coreceptor usage, infectivity, and V3 loop
glycosylation
The recombinant viruses generated were used to in-
fect GHOST indicator cells expressing CD4 (GHOST pa-
rental) and either CXCR4 (GHOST-CXCR4) or CCR5
(GHOST-CCR5). As shown in Table 1, the replacement of
the NL4-3 V3 region against the R5 tropic V3 loops of
PI-918 and PI-991 results in a NL4-3 mutant only able to
infect GHOST-CCR5 cells. Thus, the original R5-tropic
phenotype of the primary isolates PI-918 and PI-991 was
obtained only by replacing the V3 loop of the NL4-3
wild-type virus against the V3 loop of the primary isolate.
This finding indicates that changing the V3 loop was
sufficient to change the original NL4-3 tropism from X4 to
R5 monotropism. To generate a dualtropic mutant of
NL4-3, the V3 loop was replaced by a V3 loop taken from
the primary isolate PI-952. Again, the replacement of the
V3 region was sufficient to obtain a NL4-3 mutant show-
ing the original phenotype of the primary isolate. The
NL4-3 mutant, designated R5X4-952, utilized CXCR4 and
CCR5 almost equally and infected GHOST-CXCR4 as
well as GHOST-CCR5 cells.
Infection of GHOST indicator cells with mutants differ-
ing in V3 glycosylation revealed that the X4-NL4-3 vi-
ruses all lacking g15 were exclusively able to replicate in
GHOST parental cells (Table 1). These results are in
agreement with our earlier studies where g15 and g15/
g17 mutants showed higher infectivity. Here we demon-
strate that mutants lacking g14 in combination with g15
showed enhanced infectivity, too. Thus, for X4-NL4-3
monotropic glycosylation mutants the lack of g14 or g17
in combination with g15 leads to a markedly enhanced
infectivity for CXCR4 and allows infection even in
GHOST-parental cells. It is known that GHOST-parental
cells exhibit low background expression of CXCR4, cor-
responding to 10% of that observed for GHOST-CXCR4
cells. As an additional control U87-CD4 cells lacking any
CXCR4 background expression were used for infection
assays. Using the U87-CD4 cells, no infection was ob-
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served with virus mutants lacking V3 loop glycans (data
not shown).
Next we characterized the mutants differing in N-gly-
cosylation containing the V3 loop derived from the pri-
mary isolate PI-952. All five mutants containing g15 were
able to infect CCR5 as well as CXCR4 cells. A complete
loss of CCR5-dependent infectivity was identified in all
eight mutants lacking g15 or lacking g15 in addition to
other V3 loop glycans. Since the glycosylation sites g13
and g14 were lacking in the original primary isolate
PI-952, we have studied three mutants containing the
g13/14 sugars (R5X4-952, -g15Q, -g15/17). Presence of
g13 and g14 did not facilitate CCR5 usage and infection
of GHOST-CCR5 cells was completely negative in the
absence of g15 and the presence of g13/14. These data
suggest that glycans g13/14 were not involved in gp120–
CCR5 interaction. As a control, g15 mutants differing in
the first amino acid of the glycosylation site (NNT 
QNT) or the third amino acid position (NNT  NNI) were
constructed. Again, the lack of g15 was correlated to a
complete loss of CCR5 infectivity and no other combina-
tion of glycans was able to recover CCR5 usage. Inter-
estingly, the R5X4-952 mutants lacking g13/14/17 and all
the mutants lacking g15 showed higher CXCR4-depen-
dent infectivity compared to the mutants containing g15
(R5X4-952, -g14, -g14/17, -g13/14). These results are in
agreement with our data on the X4 monotropic mutants,
which also showed an enhancing CXCR4-dependent in-
fectivity due to the lack of g15. On the other hand these
data show that g15 is crucial for the NL-952 virus to use
CCR5.
Since the presence of g15 was important for CCR5
usage by the dualtropic R5X4-952 virus, we character-
ized mutants of R5 monotropic viruses R5-918 and R5-
991. R5 monotropic mutants lacking g15 (R5-918-g15;
R5-991-g15) and mutants lacking g15 in combination with
g17 (R5-991-g15/17) were tested for CCR5-specific infec-
tion. For all three mutants we observed infection of
FIG. 1. Replacing the V3 loop region in HIVNL4-3 env. (A) The V3 loop region of gp120 contains five recognition sites for N-linked glycosylation. These
five sites in the HIV-1NL4-3 gp120 sequence are designated g13, g14, g15, g16, and g17. Glycans g13, g14, g16, and g17 are high mannose (HM) glycans
and g15 is a complex (C) glycan. (B) The V3 region was replaced by cloning a V3 fragment flanked by two unique restriction sites (*, BglII, NheI) into
the env gene present in a standard cloning vector (pUCenvV3). V3 fragments were generated by PCR amplification using proviral DNA from primary
isolates PI-952, PI-991, and PI-918. Mutants, lacking glycosylation sites, were generated by site-directed mutagenesis using oligonucleotide primers
and PCR amplification. After generation of a complete env gene, the env gene was cloned into the retroviral vector pNL4-3-Bst using two unique
restriction sites (**, BstEII, BamHI) (Polzer et al., 2001).
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CCR5-expressing cells. Thus for the R5 monotropic vi-
ruses the lack of g15 does not lead to a complete loss of
CCR5-specific infection (Table 1). However, CCR5-de-
pendent infectivity was markedly reduced for those R5
mutants lacking g15 (Fig. 3). Thus, for R5 monotropic
viruses the lack of g15 was also affecting infectivity in a
negative manner. Comparing the CCR5-dependent infec-
tion rates of the R5 and R5X4 mutants lacking g15
showed that CCR5-specific infectivity was reduced by
20% for the R5-918-g15 virus, by 50% for the R5-991-g15
virus, and by 100% for the dualtropic R5X4-952-g15Q.
Thus, the reduction of CCR5-specific infectivity by g15
was higher for viruses with a lower CCR5-specific infec-
tivity and the reduction in CCR5-specific infectivity was
low for viruses with high replication rates on GHOST-
CCR5 cells (Fig. 3).
Coreceptor usage, lack of g15, and neutralization
Viruses NL4-3, NL-952, NL-991, and NL-918 with and
without g15 were tested for neutralization. As shown in
Fig. 4 NL4-3, NL-952, and NL-991 viruses containing the
g15 glycan were more resistant to neutralization by a
HIV-1 antibody-positive human serum mixture than the
viruses lacking g15. As a control, replication of viruses
was monitored in the presence of HIV-1 antibody-nega-
tive human serum mixture. X4-tropic NL4-3-g15 was neu-
tralized completely compared to the NL4-3g15 virus.
Also CXCR4-specific infection of the NL-952 virus was
neutralized more efficiently due to the lack of g15. Neu-
tralization of R5 monotropic NL-991-g15 was also more
efficient compared to the neutralization of the NL-
991g15 virus. For NL-918, no difference in neutraliza-
tion was observed for viruses g15 or g15 with normal
human serum or HIV-1 neutralizing antibodies.
Taken together, in gp120–CCR5 interaction, the lack of
g15 leads to a reduction in CCR5-dependent infectivity. A
complete loss of CCR5-dependent infectivity was ob-
served for the dualtropic mutants and a marked reduc-
tion in CCR5-usage was observed for the R5 monotropic
mutants. Reduction of CCR5-usage due to the lack of g15
was higher in R5-viruses with a low CCR5-dependent
infectivity and vice versa. In contrast, viral CXCR4-depen-
dent infectivity was enhanced due to the lack of g15 or
to the lack of g15 in combination with g14 or g17.
These data suggest that glycan g15 plays an important
and different role in gp120–coreceptor interactions due
to its enhancing effect on CCR5-specific infection and
its inhibitory effect on CXCR4-specific infection. Glycan
g15 was also involved in blocking antibody binding to
gp120.
FIG. 2. V3 sequences of X4, R5X4, and R5 tropic HIVNL4-3 mutants. The V3 region of HIVNL4-3 gp120 from amino acid position 273 to 347 was replaced
by the V3 region of a R5X4 dualtropic virus (PI-952) and against the V3 region of two R5 monotropic viruses (PI-918, PI-991). X4-NL4-3, mutants of X4
monotropic HIVNL4-3. R5X4-952, mutants of dualtropic NL4-3 containing the PI-952 V3 loop. R5-918, mutant of HIVNL4-3 containing the PI-918 V3 loop.
R5-991, mutant of HIVNL4-3 containing the PI-991 V3 loop. Bold underlined, mutated recognition sites for N-glycosylation. *, original V3 loop amino acid
sequence of the primary isolate.
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DISCUSSION
The insertion of patient-derived env sequences into
the HIVNL4-3 background is a standard technique used to
study coreceptor usage of HIV-1 (Zhang et al., 2001).
HIV-1 env is amplified from patient-derived viral RNA or
proviral DNA and is inserted into the HIVNL4-3 background
to generate recombinant viruses that can easily be ana-
lyzed (Trouplin et al., 2001; Dittmar et al., 2001). HIVNL4-3
was also used to study viral replication and coreceptor
usage in response to the presence of V3 loop glycans
(Nakayama et al., 1998; Polzer et al., 2001). In general, the
HIVNL4-3 strain is one of the standard models in HIV-1
research to study gene regulation, infectivity, neutraliza-
tion, vaccine responses, and in vitro pathogenesis.
As demonstrated by these studies, the replacement of
the HIVNL4-3 V3 region by the V3 loop region of primary
isolates was sufficient to change the original X4 pheno-
type of the HIVNL4-3 strain to R5 and R5X4. The coreceptor
usage of the R5 and R5X4 primary isolates was conferred
to HIVNL4-3. Since the coreceptor usage of recombinant
viruses was identical to the coreceptor usage of the
respective primary isolate, the present data once again
showed that the V3 loop is the most important region of
gp120 that determines the affinity of gp120 for the two
coreceptors CXCR4 and/or CCR5 (DeJong et al., 1992;
Cocchi et al., 1996).
Since the gp120 envelope is highly glycosylated, it was
suggested that the glycans are shielding the envelope to
prevent binding of neutralizing antibodies. It was shown
that glycan g15 especially was protective against neu-
tralizing monoclonal antibodies in vitro (Schonning et al.,
1996a,b) and in vivo (Cheng-Mayer et al., 1999; Malen-
baum et al., 2000). Our present data also demonstrated
the protective role of g15. In general, g15 can be seen as
an immunologically tolerated human structure which is
relevant for blocking neutralizing antibodies. Shielding
the V3 loop with host derived and therefore immunolog-
ically tolerated structures would be a powerful strategy
to protect the virus against the strong antiviral immune
response directed against the V3 loop. On the other hand
shielding the gp120 molecule might hinder HIV-1 in mak-
ing contact to the coreceptors. Our present data and data
from Polzer et al. (2001) support this theory for CXCR4-
specific infection. For gp120–CXCR4 interactions the lack
of g15 or other V3-based glycans leads to higher infec-
tivity, indicating that the sugars next to the V3 loop are
blocking gp120–CXCR4 binding. CXCR4-specific infec-
tion was also supported for those dualtropic mutants of
R5X4-952 lacking g15. The data suggest that the V3 loop
is presented in a more open conformation not shielded
FIG. 3. Lack of g15 and reduction of CCR5-specific infectivity. Infec-
tion of GHOST-CCR5 expressing cells was calculated in relation to the
mutant with the highest infectivity (infectivity of R5-918  100%). ,
presence of glycosylation site g15; , lack of g15. Shown are the
averages based on three independent experiments. The standard error
of the mean was 10%. Virus inoculums were standardized based on
p24 antigen measurements (1 ng p24/104 cells/well).
TABLE 1
Infection of GHOST Coreceptor Expressing Cell Lines with HIVNL4-3
Mutants Differing in X4 and R5 Tropism and V3 Loop Glycosylation
Virus
Presence of V3 loop
N-glycosylation sites GHOST cell infectiona
g13 g14 g15 g16 g17 Parental CXCR4 CCR5
X4-NL4-3   
-g13   
-g17   
-g15   
-g15/17   
-g14/15   
R5X4-952   
-g14   
-g14/17   
-g13/14   
-g13/14/17   
-g15Q   
-g14/15I   
-g14/15SQ   
-g14/15Q   
-g15/17   
-g14/15/17   
-g13/14/15   
-g13/14/15/17   
R5-991   
-g15   
-g15/17   
R5-918   
-g15   
a Infection of GHOST cells is expressed as the number of p24
expressing GHOST cells (foci forming units) per 100 ng of viral p24 or
per milliliter.
b A positive sign () indicates: , 1 to 10 ffu/ml; , 10 to 100 ffu/ml;
, 100 to 103 ffu/ml;,103 ffu/ml p24 positive cells covering
the well. A negative sign () indicates that there was no p24 expres-
sion detectable in any of the GHOST cells.
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FIG. 4. Neutralization of X4, R5X4, and R5 tropic HIVNL4-3 mutants. Viruses differing in coreceptor usage and presence of glycosylation site g15 were
tested for replication in GHOST-CXCR4 and GHOST-CCR5 cells (triangles: g15; squares: g15). Replication was tested in the presence of normal
human serum (black symbols) and a mixture of sera from HIV-infected individuals (white symbols) at a 1:100 dilution. Hela-P4 cells were transfected
with the proviral DNA. Cell-culture supernatants were harvested on day 2 and used for infection of U87 cells. Equal amounts of virus were added to
each well as calculated by the amount of p24 in the Hela-P4 cell culture supernatant (0.1 ng p24/3  104 cells for NL4-3 mutants; 0.25 ng p24/3 
104 cells for R5X4-952 mutants; 0.5 ng p24/3 104 cells for R5-991 and R5-918 mutants). Infection of U87 cells was monitored by a standard p24 ELISA
on days 1, 3, 5, 7, 10, and 13 after infection. Shown are the averages of triplicate wells. The standard error of the mean was 15%. Symbols: Œ, g15
and normal human serum; ‚, g15 and anti-HIV serum mix; , g15 and normal human serum; , g15 and anti-HIV serum mix.
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by the V3-based sugar. That V3 loops of V3-deglycosy-
lated mutants are presented in a more open, more ac-
cessible conformation was shown also in the context of
antibodies. Antibodies able to neutralize HIV were much
more effective against viruses lacking g15 compared to
viruses containing the V3 loop glycan (Schonning et al.,
1996a; Malenbaum et al., 2000). Thus, for CXCR4-specific
infection glycan g15 has an inhibitory function on CXCR4
usage and on antibody binding. On the other hand, lack
of g15 promotes higher X4-infectivity but makes the virus
highly sensitive to neutralizing antibody.
As stated before, the analysis of the envelope–core-
ceptor interaction is mainly based on indirect experimen-
tal approaches using viral mutants and indicator cell
lines. Based on such indirect studies there is a contro-
versy in the literature concerning which region of gp120
is responsible for interaction with the coreceptors. A
crystal structure of the gp120 core (Kwong et al., 1998)
supports the hypothesis that a conserved region of
gp120 is responsible for coreceptor binding. To obtain
crystals of gp120 it was necessary to remove the variable
loop regions V1/V2 and V3 as well as more than 90% of
the carbohydrates normally present on gp120. Another
theory proposes that the V3 loop itself binds directly to
the coreceptors. This theory is supported by the follow-
ing facts: (i) HIV mutants lacking the V3 loop are unable
to infect cells (Cao et al., 1997); (ii) single amino acid
changes promote coreceptor switch from CXCR4 to
CCR5 usage (DeJong et al., 1992); (iii) HIV replication can
be blocked by V3 peptides (Sakaida et al., 1998; Bar-
bouche et al., 2000); (iv) replacing the V3 loop against the
SDF-1 (the natural ligand of CXCR4) amino acid se-
quence allows CXCR4 usage (Yonezawa et al., 2001); and
(v) replacement of the V3 loop against the Mip1- (the
natural ligand of CCR5) sequence allows CCR5 usage
(Yonezawa et al., 2001).
This theory is furthermore supported by results ob-
tained from a direct experimental approach for V3 loop–
coreceptor interactions (Sakaida et al., 1998). A cyclized
V3 loop peptide of HIV strain IIIB (which is identical to the
V3 loop of HIVNL4-3) and cyclized V3 loop peptides corre-
sponding to other X4 or R5X4 tropic strains were binding
to CXCR4. The V3 loop peptides also inhibited infection
by X4-tropic HIV-1 in a dose-dependent manner while
other V3 peptides corresponding to a V3 loop of R5 tropic
HIV strain ADA had no effect on virus neutralization or
CXCR4 binding. Binding to CXCR4 was only observed
with cyclized peptides and the linear forms of the V3 loop
peptides showed no binding activity for CXCR4 or inhi-
bition of infection. These data indicate that the V3 loop
has to be presented in its loop conformation to bind to
the coreceptor and that the loop structure is more im-
portant for binding than the V3 loop amino acid se-
quence itself. Using V3 cyclized peptides also suggests
that binding of the V3 loop to the coreceptor is indepen-
dent of other regions of gp120 such as the V1 and V2
loop region or cellular CD4.
In the present study it was shown again that the V3
loop is the most relevant region of gp120 for coreceptor
usage and it is highly suggestive that a more open
conformation of the V3-loop is relevant for a better use to
CXCR4. As can be concluded from our data, the role of
glycan g15 for CCR5-specific infection seems to be com-
pletely different than for CXCR4. In contrast to CXCR4
glycan g15 is enhancing the binding to CCR5 and there-
fore seems to be directly involved in V3 loop–CCR5
interaction. In our study all three CCR5-specific NL-vi-
ruses showed higher R5-infectivity when the V3 loop was
glycosylated and viruses lacking g15 showed reduced
infectivity by 20, 50, and 100%. From the present data it is
not clear if the g15 effect on CCR5 usage is caused by a
direct interaction of g15 with the CCR5 coreceptor or by
an interaction of the g15 glycan with the gp120 monomer
or trimer on the viral surface. We hypothesize that g15
might interact with a region on gp120 including parts of
the V3 loop responsible for, or involved in, CXCR4 bind-
ing. The shielding of this region is blocking CXCR4 in-
teraction but has a positive effect on CCR5 usage. If no
CCR5-active domain is present on gp120, g15 has no
effect on CCR5 usage and only CXCR4 activity is modu-
lated by g15. For dualtropic viruses the shielding of the
CXCR4 region might enhance CCR5 usage. However,
due to the lack of g15 the CXCR4 region is exposed and
in this conformation the R5X4 virus is shifted to the X4
phenotype. If so, the effect of g15 might be directly linked
to the overall CCR5-specificity of the respective gp120 or
V3 loop. In R5-monotropic viruses the CXCR4-binding
region of gp120 might be mutated and less efficient and
therefore the shielding effect of g15 might be low or no
shielding is necessary anymore to support CCR5 usage.
In R5-viruses with no CXCR4-region left no binding of g15
to this region would be possible and therefore the effect
of g15 on coreceptor usage would be nondetectable. The
binding of the g15 glycan to gp120 might also prevent
antibody binding and without the intramolecular interac-
tion gp120 is more accessible to neutralizing antibodies.
To test this hypothesis, further work and a much better
understanding on the function of neutralizing antibodies
against the gp120 envelope complex are needed.
In general, the gp120 and the coreceptor are pre-
sented as membrane-bound or membrane-integrated
glycoproteins which make it highly difficult to study the
protein–protein interaction directly using them in the
form of purified proteins. Here, we have used viruses
presenting the gp120 in its native conformation and cells
expressing both receptors in their native conformation.
Based on these experiments we have demonstrated the
different role of g15 for CCR5 and CXCR4 interactions.
Since we have used identical GHOST cells only differing
in the expression of coreceptors, our data also demon-
strate that changes in V3 loop glycosylation preferentially
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influence the interaction of gp120 with the coreceptors
and not with other sugar-binding cellular proteins, i.e.,
high-mannose binding proteins (Larkin et al., 1989;
Ezekowitz et al., 1989), which probably are present on the
membrane of the parental GHOST cells as well as the
GHOST-CXCR4 or GHOST-CCR5 or U87-CD4 cell lines.
Also, infection by X4 viruses lacking g15 can be blocked
by SDF-1, the natural ligand of CXCR4. GHOST-CXCR4
and GHOST parental cell infection was shown to be
blocked by SDF-1 (Polzer et al., 2001). Thus, the lack of
g15 mainly influences the coreceptor-specific interac-
tions and has no influence on CD4 independence. This is
supported by the fact that U87 cells, expressing no
CXCR4 background activity, were not infected by the
-g14/15 mutants in contrast to the GHOST-parental cells,
expressing a low CXCR4 background activity.
The binding of the native oligomeric, functional form of
gp120 to CXCR4 or CCR5 is more complex than V3
peptide binding to coreceptors and requires conforma-
tional changes of gp120 induced as a result of binding to
CD4 (Lapham et al., 1996). In context of gp120 or the
gp120 trimer, other gp120 regions might influence the
binding of the V3 loop to CXCR4. It is conceivable that the
so-called conserved coreceptor binding site, as postu-
lated by Kwong et al. (1998), is responsible for an in-
tramolecular stabilization of the oligomeric gp120 con-
formation, holding the V3 loop inside of the molecule to
prevent exposure of the V3 loop prior to CD4 binding.
The binding of the V3 loop to this intramolecular region
might also be influenced by V3-based glycans.
In contrast to the indirect or direct studies on gp120–
CXCR4 binding, only limited data are available for gp120–
CCR5 binding. In two studies, Ogert et al. (2001) and
Pollakis et al. (2001) demonstrated that g15 played a
critical role in coreceptor utilization. Mutants of two vi-
ruses, the dualtropic strains HIV-1DH12 and HIV-1168.10, lost
CCR5 function due to the lack of g15. In our present study
we also identified the loss of CCR5 utilization by testing
V3-deglycosylated mutants of a dualtropic virus. Core-
ceptor interaction of dualtropic viruses might be more
sensitive to V3-deglycosylation since these viruses are
specific for both coreceptors, which means they are not
fully adapted to only one coreceptor such as the mono-
tropic viruses. Our observation that glycan g15 is neces-
sary for CCR5 interaction is also in agreement with V3
loop sequence data of R5 exclusive viruses (Hung et al.,
1999; Trouplin et al., 2001), showing the predominance of
g15 in these sequences.
In general, HIV infection and AIDS pathogenesis is
characterized by a change of the viral population during
progression of the disease. Early in infection CCR5-
dependent viruses are predominant and during disease
progression the emergence of HIV-1 isolates with the
capacity to use CXCR4 (Koot et al., 1993) can be ob-
served. In early infection viruses blocking antibodies by
g15 might have an advantage over viruses lacking. In
addition to the antibody-blocking function of g15 its en-
hancing effect on CCR5 binding seems to be a second
important step in the battle of HIV against the immune
responses in the early stages of HIV-1 infection. The
emergence of the CXCR4-specific, X4 tropic strains
showing faster replication and higher pathogenicity in
patients is associated with disease progression and
development of AIDS symptoms. Therefore, it is impor-
tant to understand how HIV accumulates the capacity to
use other coreceptors than CCR5. Our study also shows
that R5 monotropic viruses, which are the predominant
viruses in the early stages of infection, lost CCR5 affinity
in correlation to a deglycosylated V3 loop. This indicates
that mutations affecting the N-glycosylation site of R5
viruses might be one important step of the R5 to X4
switch. The data presented do not show why and how
the R5 exclusive viruses are gaining the use of CXCR4 to
establish the dualtropic phenotype but they do show how
such a dualtropic virus can finally switch to the more
pathogenic X4 type by a single point mutation.
We hypothesize that a virus containing V3 glycans is
protected against antibodies and can bind more effi-
ciently to CCR5 compared to viruses lacking g15. In the
early stage of HIV infection this might be an advantage
for the virus since the immune response is not impaired.
Later in infection, neutralizing antibody responses are
lost and viruses can emerge no longer neutralized. In
such a situation protection of the coreceptor-binding
domain of gp120 by g15 is no longer necessary. As a
consequence viruses can emerge lacking V3 glycans
such as g15. These viruses can now easily switch to the
CXCR4 coreceptor, allowing faster replication, and there-
fore can grow to higher levels. AIDS progression is the
consequence.
In summary, our results demonstrate that the N-linked
glycans in the V3 loop strongly influence the R5 to X4
switch. Detection of viruses lacking g15 sugars occurs
frequently in the late stage of disease and AIDS patients
(Fouchier et al., 1992; Hung et al., 1999; Nelson et al.,
2000; Trouplin et al., 2001; Saha et al., 2001), demonstrat-
ing the relevance of the glycan g15 in AIDS pathogene-
sis.
MATERIAL AND METHODS
Construction of NL4-3 mutants with R5X4
and R5 tropism
To generate viral clones differing in coreceptor usage,
we have cloned the V3 region of primary isolates in the
HIVNL4-3 backbone. To isolate the V3 sequences from
primary isolates PI-952 (R5X4-dualtropic) and PI-991 (X4-
tropic), the proviral DNA from infected human PBMC was
amplified by PCR with primers 8693 (5-CCA ATT CCC
ATA CAT TAT TGT GCC) and 8694 (5-ATA CAT TGC TTT
TCC TAC TTC CTG C). Amplified proviral DNA was se-
quenced to identify V3 sequences flanking the two sites
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to generate primers containing the two restriction sites
BglII and NheI used for further cloning procedures. After
amplification using the virus-specific BglII and NheI
primers (PI-952-BglII-for: 5-GGT AGT AAT TAG ATC TGC
CAA TTT CTC G; PI-991-BglII-for: 5-GAG ATA GTA ATT
AGA TCT GAA AAT T; PI-952-NheI-rev: 5-CCT CTT AAT
TTT GCT AGC TAC CTG; PI-991-NheI-rev: 5-AAA TTG
TTC TCT TAA TTT GCT AGC TAT), the V3 loop region was
cloned into the BglII and NheI sites, which are unique
restriction sites in the envV3 derivate (pUCenvV3).
After V3 cloning, the env gene, containing the V3 se-
quence of the primary isolate, was inserted into the
pNL4-3-Bst recombinant vector by BstEII and BamHI
cleavage to generate infectious viral clones as described
previously (Polzer et al., 2001).
Generation of NL4-3 mutants differing in the
presence of V3 glycosylation sites
The recognition sites for N-linked glycosylation were
mutated using site-directed mutagenesis and PCR am-
plification as described for the X4-NL4-3 mutants (Polzer
et al., 2001). For R5X4 tropic viruses a recognition site for
N-glycosylation was introduced by mutating the DNA
sequence coding for g13 KET to NET or NES. The glyco-
sylation site g14, DCI (originally present in PI-952) was
changed to NCT. Site g15 was changed from NNT to NNI
or QNT and the glycosylation site g17 was changed from
NNT to NNA. For the R5 tropic mutants the glycosylation
sites g15 and g17 were mutated by sequence changes
NNT to QNT.
Plasmid DNA of pNL4-3 mutants was isolated from
Escherichia coli bacteria (strain XL-1) by a standard
procedure (Macherey & Nagel, Nucleo Spin Miniprep
Kit). Purified plasmid DNA was transfected into Hela-P4
cells using the calcium phosphate technique (Chen and
Okayama, 1987). Hela-P4 cells were grown as described
in the following paragraph to generate viral superna-
tants. To generate virus supernatants of high titers and
virus that contains in vivo identical glycosylation, the
Hela cell-culture supernatants were transferred to PBMC
cell cultures. Virus production was monitored by a stan-
dard p24 antigen ELISA (Moore et al., 1990) (Aalto Bio
Reagents Ltd., Dublin, U.K.).
Virus cell culture
Hela-P4 cells were grown in Dulbecco’s modified Ea-
gle’s medium (DMEM) (Life Technologies, Karlsruhe,
Germany) supplemented with 10% fetal calf serum (FCS)
(Biochrom KG, Berlin, Germany).
Human peripheral blood mononuclear cells (PBMC)
were obtained from HIV-1 negative donors, isolated by
Ficoll–Paque gradient centrifugation, and cultivated in
RPMI cell-culture medium (PAA Laboratories GmbH,
Linz, Austria) containing 10% FCS. PBMC were stimu-
lated by adding 5 g/ml phytohemagglutinin and 100
U/ml interleukin 2 (Chiron GmbH, Ratingen, Germany).
After culturing for 7–10 days, virus production was mea-
sured by a standard p24 assay as described above.
Human osteosarcoma (GHOST) indicator cell lines
(provided by D. Littman) were cultured in DMEM (Life
Technologies), supplemented with 10% FCS. The paren-
tal GHOST cell clone (clone 34) expressing human CD4
was grown under G418 selection (500 g/ml; Life Tech-
nologies GmbH). GHOST cells expressing one of the
coreceptors CCR5 and CXCR4 were cultivated in medium
additionally supplemented with puromycin (1 g/ml;
Sigma, Deisenhofen, Germany).
Evaluation of coreceptor usage
GHOST cells expressing human CD4, CD4CCR5,
and CD4CXCR4 were used as indicator cells for the
characterization of the coreceptor usage of the NL4-3
glycosylation mutants. The monitoring and p24 immuno-
staining of infected GHOST cells was carried out as
described before (Polzer et al., 2001). In brief, GHOST
cells were infected with virus supernatants from HIV-
infected PBMC cell cultures. Equal amounts of virus
were used for infection as measured by the amount of
p24 antigen in the supernatants used for each inocula-
tion. Experiments were carried out in triplicate. Infection
of GHOST cells was monitored 4 days after infection by
a p24 staining using two mouse monoclonal anti-p24
antibodies (EVA365, EVA366, provided by the MRC AIDS
reagent project) and a secondary -galactosidase-con-
jugated goat anti-mouse monoclonal IgG antibody (Bio-
zol, Germany). Stained blue cell clusters were obtained
by staining with x-gal (5-bromo-4-chloro-3--D-galactosi-
dase) and counted. Infection of GHOST cells was ex-
pressed as foci forming units (ffu) (Chesebro and Wehrly,
1988; Clapham et al., 1992).
Evaluation of viral replication and neutralization
U87 cells (3  104 cells/well) expressing human CD4
and either CCR5 or CXCR4 were grown in 96-well cell-
culture plates (Greiner, Germany) for 24 h. Cells were
infected with equal amounts of virus according to 0.1 ng
p24 for infection with NL4-3 mutants, 0.25 ng p24 for
infections with R5X4-952 mutants, and 0.5 ng p24 for
infections using R5-918 and R5-991 mutants. Prior to
infection, virus supernatants from transfected Hela-P4
cells were incubated with HIV-positive or normal human
serum at a final dilution of 1:100 for 1 h at 37°C. Cells
were inoculated with the virus-serum mixture for 18 h.
After inoculation, the cells were washed and cell-culture
supernatants were harvested for p24 antigen detection
by a standard p24-antigen ELISA on day 1, 3, 5, 7, 10, and
13 after infection. All experiments were carried out in
triplicate using fresh supernatants from transfected
Hela-P4 cells. Virus was standardized by the amount of
p24 that was used for inoculation of GHOST or U87 cells.
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